Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

NEW YORK-- ( BUSINESS WIRE )--Hess Corporation (NYSE: HES) announced today that John Hess, Chief Executive Officer, will ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been and remains the treatment and prevention of HIV and liver ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had pressured Regeneron from all-time highs, and the firm ...